Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma / 医学前沿
Frontiers of Medicine
;
(4): 290-303, 2023.
Artigo
em Inglês
| WPRIM
| ID: wpr-982563
ABSTRACT
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer death worldwide. It is urgent to develop new drugs to improve the prognosis of ESCC patients. Here, we found benzydamine, a locally acting non-steroidal anti-inflammatory drug, had potent cytotoxic effect on ESCC cells. Benzydamine could suppress ESCC proliferation in vivo and in vitro. In terms of mechanism, CDK2 was identified as a target of benzydamine by molecular docking, pull-down assay and in vitro kinase assay. Specifically, benzydamine inhibited the growth of ESCC cells by inhibiting CDK2 activity and affecting downstream phosphorylation of MCM2, c-Myc and Rb, resulting in cell cycle arrest. Our study illustrates that benzydamine inhibits the growth of ESCC cells by downregulating the CDK2 pathway.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fosforilação
/
Benzidamina
/
Neoplasias Esofágicas
/
Apoptose
/
Linhagem Celular Tumoral
/
Proliferação de Células
/
Quinase 2 Dependente de Ciclina
/
Simulação de Acoplamento Molecular
/
Carcinoma de Células Escamosas do Esôfago
Limite:
Humanos
Idioma:
Inglês
Revista:
Frontiers of Medicine
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS